bioAffinity Technologies (BIAF) Stock Price, News & Analysis $1.39 -0.02 (-1.42%) (As of 05:19 PM ET) Add Compare Share Share Today's Range$1.39▼$1.4950-Day Range$1.15▼$1.6952-Week Range$0.95▼$3.99Volume15,000 shsAverage Volume352,676 shsMarket Capitalization$13.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media About bioAffinity Technologies Stock (NASDAQ:BIAF)bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.Read More BIAF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIAF Stock News HeadlinesDecember 9, 2023 | americanbankingnews.comHead-To-Head Contrast: bioAffinity Technologies (NASDAQ:BIAF) versus National Research (NASDAQ:NRC)November 30, 2023 | marketwatch.comBioAffinity Shares Rise on Addition to Government Pay ScheduleDecember 11, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 30, 2023 | finance.yahoo.comCMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024November 15, 2023 | finance.yahoo.combioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer ScreeningNovember 14, 2023 | finance.yahoo.combioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 6, 2023 | bizjournals.comSA biotech hire to bolster national expansionNovember 6, 2023 | finance.yahoo.combioAffinity Technologies Names Dallas J. Coleman as National Director of SalesDecember 11, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.September 7, 2023 | finance.yahoo.combioAffinity Technologies to Participate in the H.C. Wainwright Global Investment ConferenceAugust 16, 2023 | finance.yahoo.combioAffinity Technologies Second Quarter 2023 Earnings: US$0.20 loss per share (vs US$0.033 loss in 2Q 2022)August 11, 2023 | thestreet.comBioaffinity Technologies Inc ComMay 15, 2023 | bizjournals.comSA cancer detection biotech entering critical periodMay 15, 2023 | finance.yahoo.combioAffinity Technologies Reports First Quarter 2023 Financial ResultsMay 5, 2023 | fortune.comHow the workforce of the future will be more like an ‘ecosystem’May 1, 2023 | finance.yahoo.combioAffinity Technologies Names Michael Dougherty as Chief Financial OfficerApril 25, 2023 | finance.yahoo.combioAffinity Technologies Presents at Cleveland Clinic Lung Cancer SymposiumApril 5, 2023 | finance.yahoo.combioAffinity Technologies to Ring Nasdaq Closing Bell TodayApril 2, 2023 | seekingalpha.combioAffinity Technologies GAAP EPS of -$1.81, revenue of $2,500March 31, 2023 | finance.yahoo.combioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial ResultsJanuary 24, 2023 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.31%January 24, 2023 | seekingalpha.comBIAF bioAffinity Technologies, Inc.January 24, 2023 | finance.yahoo.combioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory ResearchJanuary 4, 2023 | finance.yahoo.combioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer TreatmentsDecember 19, 2022 | finance.yahoo.comArgus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)December 15, 2022 | finance.yahoo.combioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical BenchNovember 8, 2022 | finance.yahoo.combioAffinity Technologies to Report Third Quarter 2022 Financial ResultsSee More Headlines Receive BIAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/11/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIAF CUSIPN/A CIK1712762 Webwww.bioaffinitytech.com Phone210-698-5334FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,150,000.00 Net Margins-2,244.15% Pretax Margin-2,240.12% Return on Equity-80.82% Return on Assets-69.38% Debt Debt-to-Equity Ratio0.13 Current Ratio3.07 Quick Ratio3.06 Sales & Book Value Annual Sales$321,489.00 Price / Sales43.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book1.11Miscellaneous Outstanding Shares9,502,000Free Float5,293,000Market Cap$13.97 million OptionableNot Optionable Beta3.80 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Steven Girgenti (Age 77)Founder & Executive Chairman of the Board Comp: $93.33kMs. Maria Zannes J.D. (Age 67)Founder, President, CEO & Director Comp: $260.81kDr. Vivienne I. Rebel M.D. (Age 58)Ph.D., Executive VP and Chief Medical & Science Officer Comp: $238.39kMr. Michael Dougherty CPA (Age 45)M.B.A., VP & CFO Mr. Xavier T. Reveles M.S. (Age 54)Chief Operating Officer Mr. Timothy P. Zannes J.D. (Age 70)Executive VP, Secretary & General Counsel Ms. Julie Anne OvertonDirector of CommunicationsMr. Dallas J. ColemanNational Director of SalesDr. William Bauta Ph.D.Senior Vice President of TherapeuticsMore ExecutivesKey CompetitorsData Knights AcquisitionNASDAQ:DKDCAAIkido PharmaNASDAQ:AIKIiSpecimenNASDAQ:ISPCScience 37NASDAQ:SNCEOntrakNASDAQ:OTRKView All Competitors BIAF Stock Analysis - Frequently Asked Questions How have BIAF shares performed in 2023? bioAffinity Technologies' stock was trading at $1.60 on January 1st, 2023. Since then, BIAF stock has decreased by 8.1% and is now trading at $1.47. View the best growth stocks for 2023 here. When is bioAffinity Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our BIAF earnings forecast. How were bioAffinity Technologies' earnings last quarter? bioAffinity Technologies, Inc. (NASDAQ:BIAF) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. The firm had revenue of $0.30 million for the quarter. bioAffinity Technologies had a negative trailing twelve-month return on equity of 80.82% and a negative net margin of 2,244.15%. When did bioAffinity Technologies IPO? (BIAF) raised $8 million in an initial public offering on Thursday, September 1st 2022. The company issued 1,300,000 shares at a price of $6.00-$6.25 per share. WallachBeth Capital acted as the underwriter for the IPO and Craft Capital Management was co-manager. How do I buy shares of bioAffinity Technologies? Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:BIAF) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.